Coronary Artery Stent Thrombosis Clinical Trial
Official title:
The MAgnitude of Platelet Inhibition and the Pharmacokinetics of a 600 mg Loading Dose of Clopidogrel, in Different Patient CATegories (Stable Angina Versus Acute-coronary Syndromes Versus ST-elevated Myocardial Infarction).
Recent studies have demonstrated a marked interindividual variability of clopidogrel's capacity to inhibit platelet aggregation with a substantial proportion (11-34%) of the patients considered non-responders to clopidogrel treatment. Variable intestinal absorption is suggested to contribute to the inconsistencies in response to clopidogrel. However, little is known about intestinal absorption in subjects who had suffered from a stent thrombosis. The MAPCAT-study has been designed to investigate whether plasma pharmacokinetics (represented by Cmax, Tmax and the AUC) after a 600 mg loading dose are significantly different between subjects who have suffered a stent thrombosis and subjects who have not suffered a stent thrombosis.
Objectives:
The first objective of the MAPCAT-study is to investigate whether plasma pharmacokinetics
(Cmax, Tmax and AUC) of an additional 600 mg loading dose are impaired in patients with a
history of stent thrombosis.
The second objective of the MAPCAT study is to investigate whether genetic polymorphisms in
receptors, enzymes and ligands involved in the process of thrombosis and haemostasis as well
in the conversion-process of clopidogrel into its metabolites do have influence on both the
absolute magnitude of platelet inhibition and Cmax, Tmax and AUC.
;
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01689493 -
Strategy to Improve Antiplatelet Therapy Adherence After Coronary Stent Implantation
|
N/A | |
Recruiting |
NCT01300507 -
PRESTIGE: PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort
|
N/A |